Ping An Biomedical Co., Ltd. PASW

Consumer discretionary SIC 2300 - Apparel & Other Finishd Prods of Fabrics & Similar Matl NAICS Manufacturing › Apparel Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.10

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023
Revenue $4.8M——
Cost of revenue $4.7M——
Gross profit $133.4K——
SG&A $843.9K——
Total operating expenses $2.2M——
Operating income -$2.1M——
Interest expense $43.1K——
Pre-tax income -$2.1M——
Income tax $260.7K——
Net income -$1.8M——
EPS, basic -0.10——
EPS, diluted -0.10——
Shares, diluted (wtd. avg.) 18.5M18.0M18.0M

Balance sheet

Fiscal year FY2025FY2024FY2023
Cash and equivalents $164.7K$18.4K—
Receivables $2.4M——
Inventory $62.1K——
Total current assets $8.9M——
Total assets $9.6M——
Accounts payable $1.3M——
Short-term debt $1.4M——
Total current liabilities $3.2M——
Total liabilities $3.3M——
Retained earnings -$3.0M——
Total equity $6.4M——

Cash flow

Fiscal year FY2025FY2024FY2023
Operating cash flow -$902.9K——
Depreciation and amortisation $785——
Financing cash flow $6.1M——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-010078.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -2M 0 2M 4M 6M Revenue, FY2025: 4.8M Gross profit, FY2025: 133.4K Net income, FY2025: -1.8M FY2023 FY2024 FY2025
Fiscal year FY2023FY2024FY2025
Revenue — — $4.8M
Gross profit — — $133.4K
Net income — — -$1.8M

Others in SIC 2300

TickerCompanyMarket capP/ERevenue growth
LULU lululemon athletica inc. $10.45B 7.5x 4.9%
LEVI LEVI STRAUSS & CO $8.38B 14.6x 4.1%
FIGS FIGS, Inc. $3.36B 106.3x 13.6%
COLM COLUMBIA SPORTSWEAR CO $3.14B 18.9x 0.9%
UAA Under Armour, Inc. $2.00B — -3.8%
GIII G III APPAREL GROUP LTD /DE/ $1.26B 19.8x -7.0%
CRI CARTERS INC $1.20B 12.9x 1.9%
SGC SUPERIOR GROUP OF COMPANIES, INC. $204.6M 27.9x 0.1%